Evaluation of the Therapeutic Efficacy of Tripeptide Tyroserleutide (YSL) for Human Hepatocarcinoma by in Vivo Hollow Fiber Assay

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2008 Feb 12

PMID 18264678

Citations 5

Authors

Xiao-lei Li

Jun-Yan Liu

Rong Lu

Qiong Xu

Zhi-Feng Zhu

Li Wang

Chun-Lei Zhou

Jing Jia

Zheng Fu

Zhi Yao

Affiliations

Soon will be listed here.

Abstract

Tyroserleutide (YSL), extracted from spleen of pigs, is a tripeptide that has shown therapeutic efficacy in an experimental BEL-7402 human hepatocarcinoma model. The hollow fiber assay (HFA) is a solid tumor model for large-scale screening of potential anticancer compounds that minimizes expenditures of materials, time, and money. Tumor cells are cultivated within biocompatible, semipermeable hollow fibers, which are implanted in immunosuppressed mice. In this study, the HFA was used to investigate the therapeutic efficacy of YSL for human hepatocarcinoma. In vitro effects of YSL on human hepatocarcinoma cell lines BEL-7402, SMMC-7721, Hep3B, HepG2, and SK-HEP-1 were assayed by the MTS method. In vivo effects of YSL on the five human hepatocarcinoma cell lines were assayed by HFA. Mice implanted with tumor cells in hollow fibers were treated with YSL, and the effects of YSL on tumor cell populations were assessed by MTT assay. YSL significantly inhibited the proliferation of the five human hepatocarcinoma, both in vitro and in vivo (P < 0.05). The HFA is a rapid, accurate, and economical method for evaluating the inhibitory effects of drugs on different tumor cells in vivo. These results support the clinical application of YSL for treatment of human hepatocarcinoma.

Citing Articles

Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma.

Ma C, Wei T, Hua Y, Wang Z, Zhang L Int J Nanomedicine. 2021; 16:4495-4513.

PMID: 34239301 PMC: 8259945. DOI: 10.2147/IJN.S315713.

Inhibitory Effects of Multivalent Polypeptides on the Proliferation and Metastasis of Breast Cancer Cells.

Zhang Z, Li Y, Wu H, Zhang X, Zhong D, Wu Y ACS Med Chem Lett. 2019; 10(12):1620-1627.

PMID: 31857837 PMC: 6912875. DOI: 10.1021/acsmedchemlett.9b00339.

Anti-tumor pharmacological evaluation of extracts from stellera chamaejasme L based on hollow fiber assay.

Liu X, Yang Q, Zhang G, Li Y, Chen Y, Weng X BMC Complement Altern Med. 2014; 14:116.

PMID: 24684953 PMC: 3976048. DOI: 10.1186/1472-6882-14-116.

Phase I clinical trial of continuous infusion of tyroserleutide in patients with advanced hepatocellular carcinoma.

Xiao Z, Jia J, Chen L, Zou W, Chen X Med Oncol. 2011; 29(3):1850-8.

PMID: 21987077 DOI: 10.1007/s12032-011-0081-z.

Experimental mouse models for hepatocellular carcinoma research.

Heindryckx F, Colle I, Van Vlierberghe H Int J Exp Pathol. 2009; 90(4):367-86.

PMID: 19659896 PMC: 2741148. DOI: 10.1111/j.1365-2613.2009.00656.x.

References

Yao Z, Lu R, Jia J, Zhao P, Yang J, Zheng M . The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma. Peptides. 2005; 27(6):1167-72. DOI: 10.1016/j.peptides.2005.02.026. View

Webster M, Muller W . Mammary tumorigenesis and metastasis in transgenic mice. Semin Cancer Biol. 1994; 5(1):69-76. View

Hassan S, de la Torre M, Nygren P, Karlsson M, Larsson R, Jonsson E . A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828. Anticancer Drugs. 2001; 12(1):33-42. DOI: 10.1097/00001813-200101000-00005. View

Everett R . Factors affecting spontaneous tumor incidence rates in mice: a literature review. Crit Rev Toxicol. 1984; 13(3):235-51. DOI: 10.3109/10408448409003374. View

Gieni R, Li Y, HayGlass K . Comparison of [3H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods. 1995; 187(1):85-93. DOI: 10.1016/0022-1759(95)00170-f. View

Hollingshead M, Alley M, Camalier R, ABBOTT B, Mayo J, Malspeis L . In vivo cultivation of tumor cells in hollow fibers. Life Sci. 1995; 57(2):131-41. DOI: 10.1016/0024-3205(95)00254-4. View

Mattern J, Bak M, Hahn E, Volm M . Human tumor xenografts as model for drug testing. Cancer Metastasis Rev. 1988; 7(3):263-84. DOI: 10.1007/BF00047755. View

LEVY J, Leclerc J . The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?. Adv Cancer Res. 1977; 24:1-66. DOI: 10.1016/s0065-230x(08)61012-x. View

Driscoll J . The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep. 1984; 68(1):63-76. View

10.

Lu R, Jia J, Bao L, Fu Z, Li G, Wang S . Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL). Cancer Chemother Pharmacol. 2005; 57(2):248-56. DOI: 10.1007/s00280-005-0046-z. View

11.

Heffelfinger S, Hawkins H, Barrish J, Taylor L, Darlington G . SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol. 1992; 28A(2):136-42. DOI: 10.1007/BF02631017. View

12.

Buttke T, McCubrey J, Owen T . Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods. 1993; 157(1-2):233-40. DOI: 10.1016/0022-1759(93)90092-l. View

13.

Knowles B, HOWE C, Aden D . Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980; 209(4455):497-9. DOI: 10.1126/science.6248960. View

14.

Krauthauser C, Wexler R, Slee A, Kerr J . The hollow fiber assay. Methods Mol Med. 2002; 74:545-66. DOI: 10.1385/1-59259-323-2:545. View

15.

HALL L, Krauthauser C, Wexler R, Hollingshead M, Slee A, Kerr J . The hollow fiber assay: continued characterization with novel approaches. Anticancer Res. 2000; 20(2A):903-11. View

16.

Suggitt M, Bibby M . 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005; 11(3):971-81. View

17.

Monga M, Sausville E . Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia. 2002; 16(4):520-6. DOI: 10.1038/sj.leu.2402464. View